Martin Shkreli Exits Long Valeant Pharma (VRX)/short Allergan (AGN) Trade for Loss of 3%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink PartnersRaises Price Target on Allergan (AGN) Following a MEDACorp Survey
October 28, 2015 7:05 AM EDTLeerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $342.00 (from $311.00), following a 60 person MEDACorp survey of US plastic surgeons and dermatologists. Specialists in the survey were bullish on Kybella and expect the drug to increase their submental fat patient... More
BTIG Thinks Valeant (VRX) Should Just Severe Ties with Philidor; PT Cut to $175
October 26, 2015 2:53 PM EDTBTIG is cutting its price target on Valeant Pharma (NYSE: VRX) from $210 down to $175, but maintaining a Buy rating following this morning's conference call.
Analyst Timothy Chiang commented, More details were provided this morning on Valeants call highlighting its relationship with Philidor,... More
